Health Economics and Outcomes Research

An economic model comparing different types of genetic testing in metastatic non-small cell lung cancer showed that next-generation sequencing is more cost-effective than testing for one or a limited number of genes at a given time.
A new economic model may help clinicians and payers have a better understanding of the relative clinical benefits and costs of second-line treatment options for metastatic renal cell carcinoma.
A new study compared medical care cost estimates of different cancer types for patients aged at least 18 years and provided important evidence about the cost of cancer care across the age spectrum.
A recent study sought to determine if clinical benefits of novel anticancer drugs have increased over time in conjunction with increasing costs.
A recent study compared the costs and toxicities of proton radiation, stereotactic body radiotherapy, and intensity-modulated radiotherapy for younger patients with prostate cancer.
The Institute for Clinical and Economic Review has announced plans to launch a new model transparency program for its drug assessment review process.
A featured poster session at the SGO 2018 Annual Meeting on Women’s Cancer detailed the results of a study comparing the efficacy and tolerability of PARP inhibitors as maintenance treatment in BRCA-mutated platinum-sensitive relapsed ovarian cancer.
Commercial payers are spending almost twice as much on chemotherapy administered in hospital outpatient departments compared with therapy administered in physician offices.
FDA-approved CAR T-cell therapies may be associated with high costs, but the therapies are priced in alignment with their clinical value, according to an Institute for Clinical and Economic Review evidence report.
A systematic review presented at the 2018 ASCO Cancer Survivorship Symposium determined whether survivorship care plans have a positive impact on health outcomes and health care delivery.